Lunai Bioworks
LNAI
18 hedge funds and large institutions have $6.6M invested in Lunai Bioworks in 2019 Q1 according to their latest regulatory filings, with 17 funds opening new positions, increasing their positions, reducing their positions, and 1 closing their positions.
31,319% more capital invested
Capital invested by funds: $21K → $6.6M (+$6.58M)
1,600% more first-time investments, than exits
New positions opened: 17 | Existing positions closed: 1
800% more funds holding
Funds holding: 2 → 18 (+16)
0.03% more ownership
Funds ownership: 0% → 0.03% (+0.03%)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Vanguard Group
Malvern,
Pennsylvania
|
+$3.71M |
| 2 |
Goldman Sachs
New York
|
+$826K |
| 3 |
Millennium Management
New York
|
+$559K |
| 4 |
BlackRock
New York
|
+$389K |
| 5 |
ECM
ExodusPoint Capital Management
New York
|
+$239K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
UBS Group
Zurich,
Switzerland
|
-$14K |
LNAI Hedge Fund Activity: Q1 2019 in Review
18 of the 4,633 institutional investors tracked by Wall St. Rank reported a position in Lunai Bioworks (LNAI) for Q1 2019, worth a combined $6.6M — up 31,319% from $21K a quarter earlier.
Buyers outnumbered sellers: 17 funds opened new LNAI positions and 1 closed out — a net gain of 16 holders — while 0 added to existing stakes and 0 trimmed.
The largest buyer was Vanguard Group, opening a new position worth an estimated $3.71M. The largest seller was UBS Group, exiting entirely with an estimated $14K sold.
- 18 institutional investors held Lunai Bioworks (LNAI) as of Q1 2019, up from 2 in Q4 2018.
- Funds reported $6.6M of Lunai Bioworks stock for Q1 2019, up 31,319% quarter-over-quarter.
- 17 funds opened new Lunai Bioworks positions in Q1 2019 and 1 closed out, a net change of +16 holders.
- The largest Lunai Bioworks buyer in Q1 2019 was Vanguard Group, an estimated $3.71M added.
- The largest Lunai Bioworks seller in Q1 2019 was UBS Group, an estimated $14K sold.
Based on aggregated 13F filings for Q1 2019.